Wyeth Peer Comparison

NSE: WYETH | BSE: 500095

₹1,333.85

₹-30.50 (-2.24%)

As on 09-Dec-2014IST

Market cap

₹3,032 Cr

Revenue (TTM)

₹742 Cr

P/E Ratio

27.7

P/B Ratio

9.2

Div. Yield

10.9 %

Edit

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	3,032	35,535	28,533	27,960	28,524
Revenue (₹ Cr)	742	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	109.38	414.00	288.22	387.35	-371.81
Net Margin (%)	14.24	11.23	14.79	26.01	-3.93
RoE (%)	36.42	8.38	29.77	25.18	-3.85
Price to Earnings	27.72	86.88	99.00	72.39	--
Price-To-Book	9.15	7.06	21.26	16.20	3.56

Income Statement (₹ Cr)

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	679.33	4,830.36	41.58	76.11	--
Total Income	714.07	4,914.64	41.73	76.68	--
Total Expenditure	577.01	3,850.53	30.00	69.99	--
EBITDA	102.32	979.83	11.59	6.12	--
Depreciation	2.74	139.92	3.35	0.80	--
EBIT	99.58	839.91	8.24	5.32	--
Interest	0.44	83.35	2.34	1.58	--
Other Income	34.74	84.28	0.14	0.56	--
Exceptional Items	--	49.83	--	--	--
Profit before Tax	133.88	890.67	6.04	4.31	--
Provision for Tax	45.96	47.88	1.54	1.44	--
Profit after Tax	87.92	842.79	4.50	2.86	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	269.29	3,581.47	44.83	10.77	--
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	6.78	1,161.18	10.36	1.29	--
Current Liabilities	208.12	1,743.20	21.34	26.33	--
Total Liabilities	503.72	6,622.02	76.53	38.71	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	87.79	3,266.10	51.75	7.38	--
Current Assets	396.40	3,355.92	24.78	31.01	--
Total Assets	503.72	6,622.02	76.53	38.71	--
Total Debt*	2.50	1,906.08	21.09	12.17	--
Net Current Assets	188.28	1,612.72	3.44	4.68	--
Contingent Liabilities	126.37	267.40	4.70	--	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	118.83	1,476.29	6.29	-0.21	--
Cash Flow from Investing Activities	28.69	-851.62	-5.46	-2.00	--
Cash from Financing Activities	-429.59	-601.32	-0.58	2.17	--
Net Cash Inflow / Outflow	-282.08	23.35	0.25	-0.04	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	31.94	18.98	13.38	29.97	--
ROE (%)	21.03	30.04	19.08	30.26	--
ROA (%)	13.92	13.36	6.16	8.85	--
EBIT Margin (%)	20.18	22.03	28.21	8.78	--
Net Margin (%)	12.31	17.15	10.78	3.74	--
Cash Profit Margin (%)	12.93	20.32	18.86	4.81	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	0.15	-13.89	12.11	37.10	--
EBIT Growth (%)	-30.42	-49.66	21.82	30.95	--
Net Profit Growth (%)	-32.40	-46.64	58.36	39.55	--
EPS Growth (%)	-32.40	-56.04	58.36	39.55	--
Book Value Growth (%)	-52.49	36.37	21.09	32.03	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	23.01	6.59	0.00	0.00	--
Price / Book Value	7.51	1.55	0.00	0.00	--
Dividend Yield (%)	16.29	2.19	--	--	--
EV/EBITDA	13.63	5.73	3.52	2.02	--
Market Cap (₹ Cr)	2,022.77	5,016.58	0.00	0.00	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.01	0.54	0.47	1.13	--
Short term debt to equity ratio	--	0.06	0.23	0.84	--
Current Ratio	1.90	1.93	1.16	1.18	--
Quick Ratio	1.14	1.36	1.11	0.75	--
Interest Coverage	305.90	11.69	3.58	3.73	--

	Wyeth	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	7.36	9.96	33.85	17.81	--
Asset Turnover	1.11	0.77	0.57	2.35	--
Receivable days	24.61	54.33	106.93	58.46	--
Inventory Days	89.51	77.43	10.49	41.85	--
Payable days	158.44	120.43	213.33	91.25	--
Cash Conversion Cycle	-44.33	11.32	-95.91	9.06	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.